3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents

A pharmaceutical composition, comprising a 3-ureido-pyrazole compound represented by formula (I):

• wherein
• R is a C3-C6 cycloalkyl group optionally substituted with a straight or branched C1-C6 alkyl group or is a C1-C6 alkyl or arylalkyl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 aminoalkynyl or C2-C4 hydroxyalkynyl substituents;
• R1 is —(CH2)n—R3;
• n is 0 or an integer from 1 to 4;
• R3 is hydrogen, hydroxy, amino, or a group selected from the group consisting of cycloalkyl, aryl and heterocyclyl, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 aminoalkynyl or C2-C4 hydroxyalkynyl substituents;
• wherein said heterocyclyl is selected from the group consisting of benzodioxolyl, quinolyl, isoquinolyl, quinoxalyl, indolyl, optionally benzocondensed pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidyl, pyrrolidinyl, piperidinyl, benzocondensed pyiridinyl, piperazinyl, thiophenyl, and morpholinyl;
• R2 is hydrogen, or
• R2 and R1, together with the nitrogen atom to which they are bonded, form a group selected from the group consisting of piperidino, piperazino and morpholino, and said group selected from the group consisting of piperidino, piperazino and morpholino is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 aminoalkynyl or C2-C4 hydroxyalkynyl substituents;
• or a pharmaceutically acceptable salt thereof;
• provided that when n is 0 and R2 is hydrogen, R is a C3-C6 cycloalkyl group optionally substituted with a straight or branched C1-C6 alkyl group, and least one pharmaceutically acceptable carrier and/or diluent.